The MUC1 heterodimeric transmembrane glycoprotein is aberrantly overexpressed by most human carcinomas. The MUC1 C-terminal subunit localizes to mitochondria and blocks stress-induced activation of the intrinsic apoptotic pathway. How MUC1 is delivered to mitochondria is not known. The present studies demonstrate that MUC1 forms intracellular complexes with HSP70 and HSP90. We show that the MUC1 cytoplasmic domain binds directly to HSP70 in vitro. By contrast, binding of MUC1 to HSP90 in vitro is induced by c-Src-mediated phosphorylation of the MUC1 cytoplasmic domain. c-Src also increases binding of MUC1 to HSP90 in cells. In concert with these results, we show that heregulin (HRG), a ligand for ErbB receptors, activates c-Src and, in turn, stimulates binding of MUC1 to HSP90. We also show that inhibitors of c-Src or HSP90 block HRG-induced targeting of MUC1 to mitochondria and integration of MUC1 into the mitochondrial outer membrane. These findings indicate that MUC1 is delivered to mitochondria by a mechanism involving activation of the ErbB receptor-c-Src pathway and transport by the molecular chaperone HSP70/HSP90 complex.
Introduction
MUC1 is a mucin-like glycoprotein that is expressed on the apical borders of normal secretory epithelial cells (Kufe et al., 1984) . MUC1 forms a heterodimer following synthesis as a single polypeptide and cleavage of the precursor into two subunits in the endoplasmic reticulum (Ligtenberg et al., 1992 ) that may be mediated by an autocatalytic process (Levitan et al., 2005) . The >250 kDa MUC1 subunit contains variable numbers of 20 amino-acid tandem repeats that are imperfect with highly conserved variations and are modified by O-linked glycans (Gendler et al., 1988; Siddiqui et al., 1988) . MUC1-N is tethered to the cell surface by dimerization with the B23 kDa C-terminal subunit (MUC1 C-ter, MUC1-C), which includes a 58 amino-acid extracellular region, a 28 amino-acid transmembrane domain and a 72 aminoacid cytoplasmic domain (CD) (Merlo et al., 1989) . With transformation of normal epithelia to carcinomas, MUC1 is aberrantly overexpressed in the cytosol and over the entire cell membrane (Kufe et al., 1984; Perey et al., 1992) . Cell membrane-associated MUC1 is targeted to endosomes by clathrin-mediated endocytosis (Kinlough et al., 2004) . In addition, MUC1-C, but not MUC1-N, is targeted to the nucleus (Huang et al., 2003; Li et al., 2003a, b, c; Wen et al., 2003; Baldus et al., 2004; Wei et al., 2005) and mitochondria (Ren et al., 2004) .
MUC1 interacts with members of the ErbB receptor family (Li et al., 2001b, c; Schroeder et al., 2001) and with the Wnt effector, b-catenin (Yamamoto et al., 1997) . The epidermal growth factor receptor and c-Src phosphorylate the MUC1 cytoplasmic domain (MUC1-CD) on Y-46 and thereby increase binding of MUC1 and b-catenin (Li et al., 2001a, b) . Binding of MUC1 and b-catenin is also regulated by glycogen synthase kinase 3b and protein kinase Cd (Li et al., 1998; Ren et al., 2002) . MUC1 colocalizes with b-catenin in the nucleus (Li et al., 2003a, c; Wen et al., 2003; Baldus et al., 2004) and coactivates transcription of Wnt target genes (Huang et al., 2003) . Other studies have shown that MUC1 also binds directly to p53 and regulates transcription of p53-target genes (Wei et al., 2005) . Notably, overexpression of MUC1 is sufficient to induce anchorage-independent growth and tumorigenicity (Ren et al., 2002; Huang et al., 2003; Li et al., 2003b; Schroeder et al., 2004) .
Recent work has demonstrated that MUC1-C localizes to mitochondria and attenuates stress-induced apoptosis (Yin and Kufe, 2003; Ren et al., 2004) . Stimulation of ErbB receptors with heregulin (HRG) increased mitochondrial targeting of MUC1 (Ren et al., 2004) ; however, the mechanism responsible for delivery of MUC1 to mitochondria was not known. In the present work, we show that, like other preproteins without classical N-terminal mitochondrial targeting sequences (Young et al., 2003) , MUC1 associates with the molecular chaperones HSP70 and HSP90. The results also show that HRG-induced activation of the ErbB receptor-c-Src pathway stimulates binding of MUC1 to HSP90 and thereby targeting of MUC1 for integration into the mitochondrial outer membrane.
Results
Tandem affinity purification of MUC1 protein complexes To identify proteins that associate with MUC1, we cloned MUC1-C downstream to Flag and HA tags in the retroviral pOZ-N vector (Figure 1a) . Lysates from HeLa cells stably transduced with the MUC1 retrovirus or the empty retrovirus were subjected to affinity chromatography with anti-Flag conjugated to beads. The adsorbed protein complexes were separated by glycerol gradient centrifugation. Analysis of Flagpositive gradient fractions by SDS-PAGE and Coomassie blue staining showed multiple proteins that associate with MUC1 ( Figure 1b) . Identification of two MUC1-associated proteins with molecular masses of B70 and 90 kDa was determined by MALDI-TOF-MS. Mass fingerprinting and sequencing of selected peptides demonstrated identity of the smaller protein with HSP70 ( Figure 1c ). The other protein was identified as HSP90 ( Figure 1d ). By contrast, HSP70 and HSP90 were undetectable following the same analysis of proteins immunoprecipitated with anti-Flag from cells expressing the empty retroviral vector. These findings indicated that MUC1 forms intracellular complexes with the HSP70 and HSP90 chaperones.
MUC1 binds to HSP70 and HSP90
To confirm the association of MUC1 with HSP70 and HSP90, lysates from HCT116 cells that stably express MUC1 were immunoprecipitated with anti-MUC1-N or a control IgG. Immunoblot analysis of the precipitates with anti-HSP70 or anti-HSP90 confirmed that MUC1 forms complexes with both chaperones (Figure 2a) . Intensity of the HSP70 and HSP90 signals as determined by scanning densitometry indicates that MUC1 associates with approximately 0.6 and 0.4% of the total HSP70 and HSP90 pools, respectively. To determine if the MUC1-CD confers the association with HSP70 and/ or HSP90, lysates from HCT116 cells stably expressing Flag-MUC1-CD were immunoprecipitated with antiFlag. Immunoblot analysis of the precipitates demonstrated that MUC1-CD associates with both HSP70 and HSP90 (Figure 2b ). To investigate whether MUC1 interacts directly with HSP70 or HSP90, we incubated GST or GST-MUC1-CD with purified recombinant HSP proteins (Figure 2c ). Immunoblot analysis of the adsorbates showed that MUC1-CD binds to HSP70, but not HSP90 (Figure 2c ). When deletion mutants of MUC1-CD were used in similar reactions, binding to HSP70 was detected with MUC1-CD (46-72), but not MUC1-CD (1-45) (Figure 2c ), indicating that the Cterminal region of MUC1-CD confers the interaction. MUC1 is phosphorylated on Y-46 by c-Src and the pYEKV motif functions as a binding site for the c-Src SH2 domain (Li et al., 2001a) (Figure 2c ). To determine if c-Src regulates binding of MUC1-CD to HSP70 or HSP90, we incubated MUC1 with c-Src and ATP, and then added the recombinant HSPs for binding reactions at 41C. c-Src had little if any effect on binding of MUC1-CD and HSP70 (data not shown). However, c-Src induced binding of MUC1-CD to HSP90 (Figure 2d) . As a control, there was no detectable binding of HSP90 to the GST-MUC1-CD (1-45) deletion mutant (Figure 2d ). Moreover, there was no detectable binding of HSP90 to , which is phosphorylated by c-Src, suggesting that the sequences surrounding the MUC1 Y-46 site are of importance for the interaction with HSP90 ( Figure 2d ). Of note, binding of MUC1-CD to HSP90 was performed in the absence of HSP70, indicating that HSP70 is dispensable for the MUC1-HSP90 interaction in vitro. These findings indicate that MUC1-CD binds directly to HSP70 and that binding of MUC1-CD to HSP90 in vitro is mediated by a c-Src-dependent mechanism.
Activation of c-Src and phosphorylation of MUC1 on Y-46 confers binding to HSP90 in vivo When MUC1 was expressed in 293 cells in the absence or presence of c-Src, there was little effect of c-Src on binding of MUC1 to HSP70 (Figure 3a, left) . Moreover, expression of MUC1 with a Y46F mutation had no apparent effect on binding of MUC1 to HSP70 in the absence or presence of c-Src (Figure 3a, left) . By contrast, c-Src stimulated binding of MUC1 to HSP90 and the Y46F mutation attenuated this response (Figure 3a , left). These findings were confirmed in repetitive experiments (Figure 3a , right). Previous work showed that HRG stimulates targeting of MUC1-C to mitochondria by a mechanism in part dependent on the Y-46 site (Ren et al., 2004) . As shown in other cell types (Belsches-Jablonski et al., 2001; Vadlamudi et al., 2003) and as determined by autophosphorylation, HRG activated c-Src in HCT116/MUC1 cells (Figure 3b ). In addition, treatment of the HCT116/MUC1 cells with PP2, a c-Src inhibitor, blocked HRG-induced c-Src activation (Figure 3b ). Consequently, we asked if HRG regulates binding of MUC1 to HSP90. Indeed, HRG stimulation of the HCT116/MUC1 cells was associated with an increase in binding of MUC1 and HSP90 (Figure 3c , left). Consistent with involvement of c-Src, PP2 attenuated this response (Figure 3c , left). As a control, inhibition of HSP90 with geldanamycin (GA), an inhibitor of HSP90 function (Whitesell et al., 1994) , also attenuated the HRGinduced interaction between MUC1 and HSP90 ( Figure  3c immunoprecipitates from HCT116/vector cells ( Figure  3d , left). Previous work has shown that HCT116 cells stably express similar levels of wild-type MUC1 and MUC1(Y46F) (Ren et al., 2004) . Notably, the interaction between MUC1 and HSP90 was attenuated by the MUC1 Y46F mutation in control and HRG-treated cells (Figure 3d HRG stimulates binding of MUC1 at the cell membrane and in the cytosol to HSP90 MUC1 is a cell membrane-associated protein that also accumulates in the cytosol of transformed cells (Kufe et al., 1984; Perey et al., 1992; Rahn et al., 2001; Croce et al., 2003) . To assess the location of MUC1 that interacts with HSP90, whole-cell lysates and purified cell membranes from control and HRG-stimulated HCT116/MUC1 cells were immunoprecitated with anti-MUC1-N. Immunoblot analysis of the precipitates with anti-HSP90 showed that, as found for whole-cell lysates, HRG stimulates binding of MUC1 and HSP90 at the cell membrane (Figure 5a ). Intensity of the signals was assessed by densitometric scanning. The fold-increase in MUC1-HSP90 binding is expressed as the mean7s.e.m. of three separate experiments compared to that obtained with the MUC1 control (assigned a value of 1) (right). The asterisk denotes Po0.05 as compared to control. (b) HCT116/MUC1 cells were grown to 60% confluence and then incubated overnight in medium with 0.1% serum. The cells were treated with 20 ng/ml HRG for 10 min or with 10 mM PP2 for 1 h and then HRG. Anti-c-Src immunoprecipitates were immunoblotted with the indicated antibodies. (c) HCT116/ MUC1 cells were treated with 20 ng/ml HRG for 10 min, 10 mM PP2 for 1 h or 1 mM GA for 1 h. Cells were also treated with PP2 or GA for 1 h and then HRG. Anti-MUC1-N immunoprecipitates were immunoblotted with the indicated antibodies (left). The fold-increase in MUC1-HSP90 binding is expressed as the mean7s.e.m. of three separate experiments compared to that obtained with the MUC1 control (assigned a value of 1) (right). The asterisk denotes Po0.05 as compared to control. (d) HCT116/vector, HCT116/MUC1 and HCT116/MUC1(Y46F) cells were left untreated or treated with HRG for 10 min. Anti-HSP90 immunoprecipitates were immunoblotted with the indicated antibodies (left). The fold-increase in MUC1-HSP90 binding is expressed as the mean7s.e.m. of three separate experiments compared to that obtained with the MUC1 control (assigned a value of 1) (right). The asterisk denotes Po0.05 as compared to control.
Delivery of MUC1 to mitochondria J Ren et al HRG stimulation was also associated with an increase in cytosolic MUC1-C levels ( Figure 5b ). The purity of the cytosolic fraction was confirmed by immunoblotting with antibodies against the cell membrane-associated platelet-derived growth factor receptor (PDGFR), endoplasmic reticulum (ER)-associated BAP31 (Ng et al., 1997) and the mitochondriaassociated Tom20 proteins (Figure 5b ). In concert with these results, we also found that HRG increases binding of cytosolic MUC1-C and HSP90 (Figure 5c ). To confirm that HRG stimulates binding of cytosolic MUC1 to HSP90, we studied HCT116 cells that stably express Flag-MUC1-CD, which is devoid of the transmembrane domain and is expressed in the cytosol (Huang et al., 2003) . HRG stimulation of the HCT116/MUC1-CD cells had little effect on binding of MUC1-CD to HSP70 (Figure 5d ). However, like full-length MUC1, HRG stimulated binding of MUC1-CD to HSP90 (Figure 5d ), confirming that cytosolic MUC1 forms complexes with HSP90. These findings indicate that HRG stimulates binding of MUC1 at the cell membrane and in the cytosol to HSP90.
c-Src and HSP90 regulate delivery of MUC1 to mitochondria HRG stimulation is associated with targeting of MUC1-C to mitochondria (Ren et al., 2004) . To assess involvement of c-Src in mitochondrial targeting of MUC1-C, mitochondria were purified from HCT116/ MUC1 cells stimulated with HRG in the absence and presence of PP2. The results confirm that HRG induces localization of MUC1-C, and not MUC1-N, to mitochondria and show that this response is attenuated by PP2 (Figure 6a ). Equal loading of the mitochondrial lysates was confirmed by immunoblotting for the mitochondrial HSP60 protein (Figure 6a ). Densitometric scanning of the constitutive mitochondrial MUC1-C signal indicated that 0.5-1% of total cellular MUC1-C localizes to mitochondria. Treatment with GA also blocked HRG-induced targeting of MUC1 to mitochondria, consistent with the involvement of HSP90 in this response (Figure 6b ). In addition and as shown previously (Ren et al., 2004) , purity of the mitochondria was confirmed by immunoblotting with antibodies against the nuclear PCNA, cytosolic IkBa and ER-associated calreticulin proteins ( Figure 6b ). As Delivery of MUC1 to mitochondria J Ren et al an additional control, there was no detectable ErbB2 in the purified mitochondrial fraction (data not shown). To assess stability of MUC1 that constitutively resides in mitochondria, HCT116/MUC1 cells were treated with GA for 4, 8 and 16 h (Figure 6c , left). Decreases in mitochondrial MUC1 levels were detectable with GA exposures of 8 and 16 h (Figure 6c , left). Densitometric scanning of the signals indicated that GA decreases mitochondrial MUC1 with a half-life of approximately 8 h. As a control, similar exposures to GA had little effect on total intracellular MUC1 levels (Figure 6c , right). These findings indicate that MUC1 is targeted to mitochondria by a mechanism dependent on c-Src and HSP90.
MUC1 is integrated into the mitochondrial outer membrane
Complexes of HSP70 and HSP90 function in the transport of proteins, such as MUC1, without Nterminal mitochondrial localization sequences to the Delivery of MUC1 to mitochondria J Ren et al mitochondrial surface (Young et al., 2003) . Previous work has also demonstrated that mitochondrial MUC1 is an integral membrane protein that is resistant to trypsin digestion (Ren et al., 2004) . To further define the localization of MUC1, we incubated purified mitochondria in hypotonic buffer to induce swelling and disruption of the outer membrane ( Figure 7a ). As shown previously (Ren et al., 2004) , treatment of mitochondria with trypsin had no effect on MUC1, but decreased Tom20, a component of the translocase of the outer membrane (Figure 7a ). Of note, the Nterminus of Tom20 is anchored in the mitochondrial outer membrane and, as such, the Tom20 C-terminal region is susceptible to protease digestion. Trypsin had no apparent effect on Tim23, a component of the mitochondrial inner membrane (Figure 7a ). After hypotonic disruption of the outer membrane, trypsin treatment had no effect on MUC1, but was associated with partial decreases in Tim23 levels and not the matrix HSP60 protein, consistent with access of the protease to the mitochondrial inner membrane (Figure 7a ). In this regard, the region of Tim23 recognized by anti-Tim23 extends into the inter membrane space from the surface of the mitochondrial inner membrane (Moro et al., 1999) . To further assess the localization of MUC1, we permeabilized the mitochondrial outer membrane with digitonin. Treatment with 0.5 or 1.0% digitonin alone had no effect on MUC1 or mitochondrial proteins associated with the outer (Tom20) or inner (Tim23 and Tim44) membranes (Figure 7b ). However, treatment of the mitochondria with both digitonin and trypsin resulted in complete digestion of MUC1, Tom20 and Tim23 (Figure 7c ). By contrast, digitonin and trypsin had little effect on Tim44, a protein associated with matrix face of the mitochondrial inner membrane (Figure 7c ). These findings collectively indicate that MUC1 is embedded in the mitochondrial outer membrane.
Discussion

MUC1 associates with HSP70 and HSP90
Most mitochondrial proteins are encoded in the nucleus and are imported into mitochondria by translocation complexes in the outer and inner mitochondrial membranes. Certain mitochondrial proteins contain Nterminal mitochondrial targeting sequences and interact with Tom20 in the outer mitochondrial membrane (Truscott et al., 2003) . Other mitochondrial proteins contain internal targeting sequences and interact with the Tom70 receptor (Truscott et al., 2003) . The mechanisms by which these proteins are delivered to mitochondria are not well understood. However, recent work showed that mitochondrial proteins with internal targeting sequences are delivered to Tom70 by a complex of HSP70 and HSP90 (Young et al., 2003) . We therefore reasoned that MUC1, which has no identifiable N-terminal mitochondrial targeting sequence and localizes to mitochondria as an integral membrane protein (Ren et al., 2004) , might be transported to mitochondria by these chaperones. Using tandem affinity purification of MUC1 complexes and MALDI-TOF-MS, the present studies show that MUC1 forms intracellular complexes with HSP70 and HSP90. These results were confirmed by showing that MUC1 at the cell membrane and in the cytosol co-precipitates with HSP70 and HSP90. We also found that the MUC1 cytoplasmic tail is sufficient for conferring the association with HSP70 and HSP90 in cells. Moreover, MUC1-CD interacted with HSP70 and HSP90 in vitro. These findings thus indicated that MUC1 forms complexes with HSP70 and HSP90, and that these chaperones might contribute to mitochondrial targeting of MUC1.
HRG-induced activation of c-Src targets MUC1 binding to HSP90
MUC1-C and not MUC1-N is targeted to mitochondria (Ren et al., 2004) . The mechanism by which MUC1-C disassociates from MUC1-N is not known and is beyond the scope of the present studies, which focus on how MUC1-C is delivered to mitochondria. In this Delivery of MUC1 to mitochondria J Ren et al regard, previous work demonstrated that HRG stimulates targeting of MUC1-C to mitochondria (Ren et al., 2004) . Moreover, constitutive and HRG-induced targeting of MUC1-C to mitochondria are both attenuated by the Y46F mutation (Ren et al., 2004) . (Li et al., 2001a) . In addition, b-catenin associates with the MUC1 serine-rich motif adjacent to the Y-46 site (Yamamoto et al., 1997) (Figure 2c ). Our in vitro binding data indicate that HSP70 binds to the MUC1 cytoplasmic tail in the same region as b-catenin. These data suggested that MUC1 may form exclusive complexes with bcatenin and with HSP70. In this regard, there was no detectable b-catenin associated with MUC1 that was delivered to the mitochondrial outer membrane. These findings collectively support a model in which c-Src phosphorylation regulates HSP90 binding to the client MUC1 protein for delivery to mitochondria. Recent work has shown that v-Src also regulates binding of the neural Wiskott-Aldrich syndrome protein to HSP90; however, in this setting, HSP90 protects the client protein from proteosomal degradation (Park et al., 2005) .
MUC1 is targeted for integration into the mitochondrial outer membrane HSP70 functions in the folding of newly synthesized proteins (Bukau et al., 2000; Hartl and Hayer-Hartl, 2002) and cooperates with HSP90 in targeting preproteins to the mitochondrial receptor Tom70 (Young et al., 2003) . Binding of HSP70 and HSP90 to Tom70 are in turn required for preprotein import (Young et al., 2003) . GA, an inhibitor of the ATPdriven HSP90 chaperone cycle (Young and Hartl, 2000) , attenuated HRG-induced binding of MUC1 to HSP90 and targeting of MUC1 to mitochondria, consistent with delivery by a HSP90-dependent mechanism (Figure 7d ). In further support of HSP90-mediated delivery, GA decreased the constitutive localization of MUC1 to mitochondria without affecting total intracellular MUC1 pools. In previous work, treatment of purified mitochondria with trypsin had no effect on MUC1 (Ren et al., 2004) . Moreover, analysis of purified mitochondria incubated in alkaline sodium carbonate indicated that MUC1 is an integral membrane protein (Ren et al., 2004) . In the present studies, mitochondria were treated with hypotonic buffer to disrupt the outer membrane (Ryan et al., 2001) . Under these conditions, trypsin had no effect on MUC1, but decreased Tim23, a mitochondrial inner membrane protein that is exposed in the inter membrane space (Moro et al., 1999) . Mitochondria were also treated with low levels of digitonin to selectively permeabilize the outer membrane. Permeabilization per se had no effect, but when combined with trypsin was associated with digestion of MUC1. As controls, this approach also resulted in digestion of Tim23, but had little effect on Tim44 which is buried in the matrix face of the mitochondrial inner membrane (Wada and Kanwar, 1998; Truscott et al., 2003) . These findings thus collectively support integration and embedding of MUC1 into the mitochondrial outer membrane (Figure 7d ). In concert with these results, our ongoing work indicates that the transmembrane domain is necessary for localization of MUC1 within mitochondria. Importantly, MUC1 attenuates release of mitochondrial apoptogenic factors in the response to stress (Ren et al., 2004) . How MUC1 protects against activation of the intrinsic apoptotic pathway is presently not known. However, integration of MUC1 into the mitochondrial outer membrane could interfere with localization of the proapoptotic Bcl-2 subfamily members and thereby neutralization of the antiapoptotic Bcl-2/Bcl-x L proteins.
Experimental procedures
Cell culture Human HCT116/vector, HCT116/MUC1, HCT116/ MUC1(Y46F) (Ren et al., 2004) and HCT116/MUC1-CD (Huang et al., 2003) cells were cultured in Dulbecco's modified Eagle's medium/F12 with 10% heat-inactivated fetal bovine serum (HI-FBS), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Human HeLa cervical carcinoma, 293 embryonal kidney and MCF-7 breast cancer cells were grown in Dulbecco's modified Eagle's medium containing 10% HI-FBS, antibiotics and L-glutamine. Human ZR-75-1 breast cancer cells were cultured in RPMI1640 medium containing 10% HI-FBS, antibiotics and L-glutamine. Cells were grown to 60% confluence and then maintained overnight in medium with 0.1% serum before treatment with HRG (20 ng/ml; Calbiochem-Novabiochem, LaJolla, CA, USA). Cells were also treated with PP2 (10 mM; Calbiochem-Novabiochem) or geldanamycin (GA; 1 mM; Calbiochem-Novabiochem).
Tandem affinity purification of MUC1 protein complexes
The procedure for purification and analysis of intracellular protein complexes has been described (Ogawa et al., 2002; Shi et al., 2003) . In brief, MUC1-C was cloned downstream to HA and Flag tags in the retroviral pOZ-N vector, which expresses the IL-2 receptor (Figure 1a ). HeLa cells were transduced with retroviruses expressing MUC1 or the empty control vector and selected with IL-2-coupled magnetic beads. Intracellular protein complexes were purified by affinity chromatography using anti-Flag conjugated to beads. The adsorbed proteins were separated by centrifugation in 10-40% glycerol gradients. The gradient fractions reactive by immunoblotting with anti-Flag were subjected to electrophoresis in 4-20% polyacrylamide/ SDS gels and stained with Coomassie blue. Proteins bands were excised and analysed by MALDI-TOF-MS.
Immunoprecipitation and immunoblotting
Equal amounts of protein from cell lysates were incubated with anti-MUC1-N (antibody DF3) (1), anti-Flag (Sigma-Aldrich, St Louis, MO, USA), anti-cSrc (Upstate Biotechnology, Lake Placid, NY, USA), anti-HSP90 (BD Biosciences PharMingen, San Diego, CA, USA) or normal mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 41C. Immune complexes were prepared as described (Li et al., 1998) and subjected to immunoblot analysis with anti-HSP70, anti-HSP90, anti-MUC1-N, anti-MUC1-C (Ab5; Neomarkers, Fremont, CA, USA), anti-phospho-c-Src (Tyr416) (Cell Signaling Technology, Beverly, MA, USA) or anti-c-Src. Lysates not subjected to immunoprecipitation were immunoblotted with anti-MUC1-C, anti-HSP60 (Stressgen Biotechnologies, Victoria, BC, Canada), anti-PDGFR (Santa Cruz Biotechnology), anti-BAP31 (Abcam, Cambridge, MA, USA), anti-PCNA (Calbiochem-Novabiochem), anti-IkBa (Santa Cruz Biotechnology), anti-calreticulin (Stressgen Biotechnologies), anti-Tom20 (BD Biosciences), anti-Tim23 (BD Biosciences), anti-Tim44 (BD Biosciences) or antib-actin (Sigma-Aldrich). Reactivity was detected with horseradish peroxidase-conjugated secondary antibodies and chemiluminescence (Perkin-Elmer Life Sciences, Boston, MA, USA). Intensity of the signals was determined by densitometric scanning. Statistical significance was determined by Student's t-test.
Cell transfections 293 cells were transiently transfected with pIRES-puro2-MUC1, pIRES-puro2-MUC1(Y46F) or pCMV-c-Src (Li et al., 2001a) in the presence of LipofectAMINE (Invitrogen Life Technologies, Carlsbad, CA, USA).
Binding studies
Sequences encoding MUC1-CD, MUC1-CD(1-45) or MUC1-CD(46-72) were amplified by PCR and cloned into the pGEX-4T vector (Amersham Biosciences, Piscataway, NJ, USA). Purified GST-MUC1-CD fusion proteins bound to glutathione beads were incubated with purified recombinant human HSP70 or HSP90 (Stressgen Biotechnologies) for 1 h at 41C. In other experiments, the purified GST-fusion proteins bound to glutathione beads were incubated with or without 50 ng c-Src (Upstate Biotechnology) in the presence of 200 mM ATP for 20 min at 301C. HSP90 was then added for 1 h at 41C. Precipitated proteins were subjected to immunoblot analysis with anti-HSP70 or anti-HSP90.
Subcellular fractionation
Cell membranes and mitochondria were purified as described (Kharbanda et al., 1996; Ren et al., 2004) . Cytosolic fractions were purified as described (Kharbanda et al., 1996; Datta et al., 2000) . The mitochondria (200 mg) were suspended in 40 ml SM buffer (10mM MOPS-KOH, pH 7.2, 250 mM sucrose) and then divided into two equal aliquots (Ryan et al., 2001) . SM buffer (180 ml) was added to one aliquot. Hypotonic buffer (10 mM MOPS-KOH, pH 7.2; 180 ml) was added to the other aliquot. The samples were incubated for 15 min on ice and then left untreated or digested with 60 mg/ml trypsin (Sigma-Aldrich) for 15 min at 41C. In other experiments, purified mitochondria in suspension buffer (5 mM HEPES, pH 7.4, 210 mM mannitol, 70 mM sucrose, 100 mM KCl, and 1 mM EGTA) were treated with 0.5 or 1% digitonin (Sigma-Aldrich) for 15 min at 41C. Alternatively, the mitochondria were incubated with 0.5% digitonin for 1 min at 41C, diluted with suspension buffer and then treated with 60 mg/ml trypsin for 15 min at 41C.
